Recombinant DNA technology in drug discovery

Authors

  • Dr. Irfan Ahmad Khan Clinical Researcher/ Senior Resident, Department of Pharmacology, J.N.M.C.H., A.M.U, ALIGARH, U.P., INDIA– 202002

Keywords:

Recombinant DNA, Hybridoma technique, Monoclonal Antibodies, Antibiotics, Vaccines

Abstract

Recombinant DNA (rDNA) technology has made a revolutionary impact in the area of human healthcare by enabling mass production of safe, pure and effective rDNA expression products. Constructing a recombinant DNA molecule involves cutting the DNA into fragments with restriction endonucleases and rejoining the fragments in novel arrangements with ligase. Currently, several categories of rDNA products, viz. hormones of therapeutic interest, haemopoietic growth factors, blood coagulation products, thrombolytic agents, anticoagulants, interferons, interleukins and therapeutic enzymes are being produced using rDNA technology for human use.

Downloads

Published

2017-04-26

How to Cite

Dr. Irfan Ahmad Khan. (2017). Recombinant DNA technology in drug discovery. World Journal of Pharmaceutical Sciences, 5(5), 78–80. Retrieved from https://wjpsonline.com/index.php/wjps/article/view/recombinant-dna-technology-drug-discovery

Issue

World J Pharm Sci 2017; 5(5): 78-202

Section

Editorial

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.